Mab cs1 4

Manufactured by Agilent Technologies

Sourced in Germany

The MAb CS1-4 is a laboratory equipment product manufactured by Agilent Technologies. It is a monoclonal antibody designed for use in various biological and analytical applications. The core function of the MAb CS1-4 is to serve as a detection reagent for the identification and quantification of target analytes in samples.

Automatically generated - may contain errors

Lab products found in correlation

Ultratek hrp anti polyvalent lab pack, by ScyTek Laboratories (1 mentions)

3 protocols using mab cs1 4

Immunohistochemical Profiling of EBV Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed to detect and localize EBV latent and lytic protein expression, using the following antibodies: LMP1 (mAb CS1-4, Dako); LMP2A (mAb 15F9, Abcam); EBNA2 (clones 1E6 and R3, kindly provided by Dr. Kremmer, Forschungszentrum fur Umwelt und Gesundheit GmbH, Institut fur Immulogie, Munchen, Germany); EBNA3A (Sheep polyclonal, Abcam); BMRF1 (mAb G3-E31, Abcam), as described by Cohen et al.23 (link). The positive controls were performed in FFPE EBV+ cells lines (Raji and P3HR1, for EBNA2 and EBNA3A, respectively), P3HR1 treated with TPA (12-O-tetradecanoylphorbol-13-acetate, Sigma) to stimulate lytic infection (for BMRF1), FFPE EBV positive diffuse large B-cell lymphoma (for EBERs) and Hodgkin Lymphoma (for LMP1 and 2A). As negative controls we tested the specific primary antibody in FFPE tonsils from EBV sero-negative patients and also performed the same method without the primary antibody. This set of antibodies allowed us to establish the EBV latency profile.

Vistarop A.G., Cohen M., De Matteo E., Preciado M.V, & Chabay P.A. (2016). Analysis of Epstein-Barr virus infection models in a series of pediatric carriers from a developing country. Scientific Reports, 6, 23303.

+ Open protocol

+ Expand

Immunohistochemical Detection of EBV Latent Proteins

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC for LMP1 (mAb CS1–4, Dako), LMP2A (clone 15F9, Abcam, Cambridge, UK), and EBNA2 (clones 1E6 and R3, kindly provided by Dr. Kremmer, Institut fur Immulogie, Munchen, Germany) were used to detect and localize EBV latent protein expression in tonsils and HL biopsies. Antigen unmasking with sodium citrate buffer (pH 6) in a microwave oven for 10 min was performed. All antibodies were incubated overnight at 4 °C. IHC detection primary antibody was carried out using a universal streptavidin–biotin complex-peroxidase detection system (UltraTek HRP Anti-Polyvalent Lab Pack, ScyTek, West Logan, UT, USA) according to the manufacturer’s instructions. In the tonsillectomies, LMP1 expression was employed in order to discriminate EBV+ and EBV-GC in all cases, given the fact that we have previously observed LMP1+ expression in all EBERs+ cases [10 (link)]. Once determined, LMP2A and EBNA2 expression and microenvironment compositions around infected and noninfected GC were compared.

Vistarop A., Jimenez O., Cohen M., De Matteo E., Preciado M.V, & Chabay P. (2020). Differences in Epstein-Barr Virus Characteristics and Viral-Related Microenvironment Could Be Responsible for Lymphomagenesis in Children. Pathogens, 9(1), 68.

+ Open protocol

+ Expand

EBV Latency Profiling by IHC

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC for LMP1 (mAb CS1-4, Dako) and EBNA2 (clones 1E6 and R3, kindly provided by Dr. Kremmer, Institut fur Immulogie, Munchen, Germany) was used to detect and localize EBV latent protein expression. A FFPE EBV-positive cell line was used as positive control, whereas an isotype control was used as negative control, according to each immune staining in specific tissue. We defined latency profiles based on LMP1 and EBNA2 expression, as has been previously described [19] (link).
LMP1 expression was employed to discriminate EBV+ and EBV-cases and positive and negative zones within them, given the fact that we have previously observed LMP1+ expression in all EBERs+ cases (18) (link), even in a few EBERs-ones. To validate the results made in the EBV-zones from EBV+ cases that were used in the present work; we contrasted immune cell counts with a group of EBV-cases (n = 7). As this analysis displayed no statistical differences (p > 0.05, Mann-Whitney test), we considered valid to compare microenvironment composition around infected and non-infected zones within EBV-positive cases.

Vistarop A.G., Cohen M., Huaman F., Irazu L., Rodriguez M., De Matteo E., Preciado M.V, & Chabay P.A. (2018). The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control. Medical microbiology and immunology, 207(5-6).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!